mRNA Lipid Nanoparticles for Cell Engineering in Vivo and in Vitro: Current Applications and Future Directions

Abstract

Messenger RNA-lipid nanoparticles (mRNA-LNPs) serve as a revolutionary platform, enabling precise and transient protein expression for both in vivo and in vitro cell engineering without genomic integration. Recent breakthroughs in mRNA design and LNP formulation have expanded their applications across immunotherapy, regenerative medicine, and genome editing. However, challenges such as off-target delivery, immunogenicity, and inadequate organ-specific targeting limit their broader therapeutic utility. This review systematically elaborates the design principles of mRNA-LNPs, including mRNA structural elements and functional lipid components that facilitate endosomal escape. It summarizes recent advances in their applications for cell engineering, both ex vivo and in vivo. Key challenges related to delivery precision and immunogenicity are thoroughly analyzed, alongside strategies to improve targeting through administration routes, surface modifications, and endogenous targeting mechanisms. The article also outlines main directions for developing next-generation mRNA-LNPs. Overall, this review will support further research on mRNA-LNPs and promote their clinical translation in the field of cell engineering.

Keywords

cell engineering / lipid nanoparticles / mRNA technology / targeted delivery

References

[1] N. Sultana, A. Magadum, Y. Hadas, et al., “Optimizing Cardiac Delivery of Modified mRNA,” Molecular Therapy 25, no. 6 (2017): 1306–1315.

[2] V. F. I. Van Tendeloo, P. Ponsaerts, and Z. N. Berneman, “mRNA-based Gene Transfer as a Tool for Gene and Cell Therapy,” Current Opinion in Molecular Therapeutics 9, no. 5 (2007): 423–431.

[3] K. Paunovska, C. D. Sago, C. M. Monaco, et al., “A Direct Comparison of in Vitro and in Vivo Nucleic Acid Delivery Mediated by Hundreds of Nanoparticles Reveals a Weak Correlation,” Nano Letters 18, no. 3 (2018): 2148–2157.

[4] P. Midoux and C. Pichon, “Lipid-based mRNA Vaccine Delivery Systems,” Expert Review of Vaccines 14, no. 2 (2015): 221–234.

[5] D. Song, Y. Zhao, Z. Wang, et al., “Tuning Lipid Nanoparticles for RNA Delivery to Extrahepatic Organs,” Advanced Materials 36, no. 44 (2024): e2401445.

[6] S. Qin, X. Tang, Y. Chen, et al., “mRNA-based Therapeutics: Powerful and Versatile Tools to Combat Diseases,” Signal Transduct Tar 7, no. 1 (2022): 166.

[7] M. D. Buschmann, M. J. Carrasco, S. Alishetty, et al., “Nanomaterial Delivery Systems for mRNA Vaccines,” Vaccines 9, no. 1 (2021): 65.

[8] N. A. C. Jackson, K. E. Kester, D. Casimiro, et al., “The Promise of mRNA Vaccines: A Biotech and Industrial Perspective,” NPJ Vaccines 5 (2020): 11.

[9] Y. Barenholz, “Liposome Application: Problems and Prospects,” Current Opinion in Colloid & Interface Science 6, no. 1 (2001): 66–77.

[10] R. Tenchov, R. Bird, A. E. Curtze, et al., “Lipid Nanoparticles─from Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement,” ACS Nano 15, no. 11 (2021): 16982–17015.

[11] B. Chen, W. Dai, B. He, et al., “Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment,” Theranostics 7, no. 3 (2017): 538–558.

[12] G. Navarro, M. Gómez-Autet, P. Morales, et al., “Homodimerization of CB(2) Cannabinoid Receptor Triggered by a Bivalent Ligand Enhances Cellular Signaling,” Pharmacological Research 208 (2024): 107363.

[13] M. M. Billingsley, N. Singh, and P. Ravikumar, “Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering,” Nano Letters 20, no. 3 (2020): 1578–1589.

[14] M. M. Billingsley, A. G. Hamilton, D. Mai, et al., “Orthogonal Design of Experiments for Optimization of Lipid Nanoparticles for mRNA Engineering of CAR T Cells,” Nano Letters 22, no. 1 (2022): 533–542.

[15] Z. Ye, J. Chen, X. Zhao, et al., “In Vitro Engineering Chimeric Antigen Receptor Macrophages and T Cells by Lipid Nanoparticle-Mediated mRNA Delivery,” ACS Biomater Sci Eng 8, no. 2 (2022): 722–733.

[16] J. Philipp, A. Dabkowska, A. Reiser, et al., “pH-dependent Structural Transitions in Cationic Ionizable Lipid Mesophases Are Critical for Lipid Nanoparticle Function,” PNAS 120, no. 50 (2023): e2310491120.

[17] X. Hou, T. Zaks, R. Langer, et al., “Lipid Nanoparticles for mRNA Delivery,” Nature Reviews Materials 6, no. 12 (2021): 1078–1094.

[18] J. A. Kulkarni, M. M. Darjuan, J. E. Mercer, et al., “On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA,” ACS Nano 12, no. 5 (2018): 4787–4795.

[19] D. Sacks, B. Baxter, B. C. V. Campbell, et al., “Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke,” Int J Stroke 13, no. 6 (2018): 612–632.

[20] Y. Sato, H. Matsui, N. Yamamoto, et al., “Highly Specific Delivery of siRNA to Hepatocytes Circumvents Endothelial Cell-mediated Lipid Nanoparticle-associated Toxicity Leading to the Safe and Efficacious Decrease in the hepatitis B Virus,” J Control Release 266 (2017): 216–225.

[21] M. Viard, H. Reichard, B. A. Shapiro, et al., “Design and Biological Activity of Novel Stealth Polymeric Lipid Nanoparticles for Enhanced Delivery of Hydrophobic Photodynamic Therapy Drugs,” Nanomedicine-Uk 14, no. 7 (2018): 2295–2305.

[22] M. L. Immordino, F. Dosio, and L. Cattel, “Stealth Liposomes: Review of the Basic Science, Rationale, and Clinical Applications, Existing and Potential,” Int J Nanomedicine 1, no. 3 (2006): 297–315.

[23] G. Prakash, A. Shokr, N. Willemen, et al., “Microfluidic Fabrication of Lipid Nanoparticles for the Delivery of Nucleic Acids,” Advanced Drug Delivery Reviews 184 (2022): 114197.

[24] W. N. Ke and K. A. Afonin, “Exosomes as Natural Delivery Carriers for Programmable Therapeutic Nucleic Acid Nanoparticles (NANPs),” Adv Drug Deliver Rev 176 (2021): 113835.

[25] Z. S. Badieyan and T. Evans, “Concise Review: Application of Chemically Modified mRNA in Cell Fate Conversion and Tissue Engineering,” Stem Cell Transl Med 8, no. 8 (2019): 833–843.

[26] K. Karikó and D. Weissman, “Naturally Occurring Nucleoside Modifications Suppress the Immunostimulatory Activity of RNA: Implication for Therapeutic RNA Development,” Curr Opin Drug Disc 10, no. 5 (2007): 523–532.

[27] N. Hoshyar, S. Gray, H. B. Han, et al., “The Effect of Nanoparticle Size on Pharmacokinetics and Cellular Interaction,” Nanomedicine-Uk 11, no. 6 (2016): 673–692.

[28] C. Baum, O. Kustikova, U. Modlich, et al., “Mutagenesis and Oncogenesis by Chromosomal Insertion of Gene Transfer Vectors,” Human Gene Therapy 17, no. 3 (2006): 253–263.

[29] J. T. Bulcha, Y. Wang, H. Ma, et al., “Viral Vector Platforms Within the Gene Therapy Landscape,” Signal Transduct Tar 6, no. 1 (2021): 53.

[30] S. E. Raper, N. Chirmule, F. S. Lee, et al., “Fatal Systemic Inflammatory Response Syndrome in a Ornithine Transcarbamylase Deficient Patient Following Adenoviral Gene Transfer,” Molecular Genetics and Metabolism 80, no. 1-2 (2003): 148–158.

[31] S. J. Howe, M. R. Mansour, K. Schwarzwaelder, et al., “Insertional Mutagenesis Combined With Acquired Somatic Mutations Causes Leukemogenesis Following Gene Therapy of SCID-X1 Patients,” Journal of Clinical Investigation 118, no. 9 (2008): 3143–3150.

[32] M. P. Stewart, A. Sharei, X. Ding, et al., “In Vitro and Ex Vivo Strategies for Intracellular Delivery,” Nature 538, no. 7624 (2016): 183–192.

[33] S. Muro, “Challenges in Design and Characterization of Ligand-targeted Drug Delivery Systems,” J Control Release 164, no. 2 (2012): 125–137.

[34] E. J. Sayers, S. E. Peel, A. Schantz, et al., “Endocytic Profiling of Cancer Cell Models Reveals Critical Factors Influencing LNP-Mediated mRNA Delivery and Protein Expression,” Molecular Therapy 27, no. 11 (2019): 1950–1962.

[35] E. Kon, I. Hazan-Halevy, D. Rosenblum, et al., “Resveratrol Enhances mRNA and siRNA Lipid Nanoparticles Primary CLL Cell Transfection,” Pharmaceutics 12, no. 6 (2020): 520.

[36] N. Nath, B. Godat, C. Zimprich, et al., “Homogeneous Plate Based Antibody Internalization Assay Using pH Sensor Fluorescent Dye,” Journal of Immunological Methods 431 (2016): 11–21.

[37] H. B. Gong and T. Urlacher, “A Homogeneous Fluorescence-based Method to Measure Antibody Internalization in Tumor Cells,” Analytical Biochemistry 469 (2015): 1–3.

[38] C. Lorenz, M. Fotin-Mleczek, G. Roth, et al., “Protein Expression From Exogenous mRNA Uptake by Receptor-mediated Endocytosis and Trafficking via the Lysosomal Pathway,” Rna Biology 8, no. 4 (2011): 627–636.

[39] Z. Wu and T. Li, “Nanoparticle-Mediated Cytoplasmic Delivery of Messenger RNA Vaccines: Challenges and Future Perspectives,” Pharmaceutical Research 38, no. 3 (2021): 473–478.

[40] D. V. Schaffer, N. A. Fidelman, and N. Dan, “Vector Unpacking as a Potential Barrier for Receptor-mediated Polyplex Gene Delivery,” Biotechnology and Bioengineering 67, no. 5 (2000): 598–606.

[41] D. S. Dimitrov, “Virus Entry: Molecular Mechanisms and Biomedical Applications,” Nature Reviews Microbiology 2, no. 2 (2004): 109–122.

[42] L. M. P. Vermeulen, S. C. De Smedt, K. Remaut, et al., “The Proton Sponge Hypothesis: Fable or Fact?,” European Journal of Pharmaceutics and Biopharmaceutics 129 (2018): 184–190.

[43] L. T. Johnson, D. Zhang, K. Zhou, et al., “Lipid Nanoparticle (LNP) Chemistry Can Endow Unique in Vivo RNA Delivery Fates Within the Liver That Alter Therapeutic Outcomes in a Cancer Model,” Mol Pharm 19, no. 11 (2022): 3973–3986.

[44] Y. Lee, M. Jeong, J. Park, et al., “Immunogenicity of Lipid Nanoparticles and Its Impact on the Efficacy of mRNA Vaccines and Therapeutics,” Experimental & Molecular Medicine 55, no. 10 (2023): 2085–2096.

[45] J. O. You and D. T. Auguste, “Nanocarrier Cross-linking Density and pH Sensitivity Regulate Intracellular Gene Transfer,” Nano Letters 9, no. 12 (2009): 4467–4473.

[46] Y. Hu, T. Litwin, and A. R. Nagaraja, “Cytosolic Delivery of Membrane-impermeable Molecules in Dendritic Cells Using pH-responsive Core-shell Nanoparticles,” Nano Letters 7, no. 10 (2007): 3056–3064.

[47] M. J. Mitchell, M. M. Billingsley, and R. M. Haley, “Engineering Precision Nanoparticles for Drug Delivery,” Nat Rev Drug Discovery 20, no. 2 (2021): 101–124.

[48] R. C. Larson and M. V. Maus, “Recent Advances and Discoveries in the Mechanisms and Functions of CAR T Cells,” Nature Reviews Cancer 21, no. 3 (2021): 145–161.

[49] T. DiTommaso, J. M. Cole, L. Cassereau, et al., “Cell Engineering With Microfluidic Squeezing Preserves Functionality of Primary Immune Cells in Vivo,” PNAS 115, no. 46 (2018): E10907–e14.

[50] R. Kitte, M. Rabel, R. Geczy, et al., “Lipid Nanoparticles Outperform Electroporation in mRNA-based CAR T Cell Engineering,” Mol Ther Methods Clin Dev 31 (2023): 101139.

[51] Y. Zhang, F. Xie, Y. Yin, et al., “Immunotherapy of Tumor RNA-Loaded Lipid Nanoparticles against Hepatocellular Carcinoma,” Int J Nanomedicine 16 (2021): 1553–1564.

[52] Y. Zhang, X. Hou, S. Du, et al., “Close the Cancer-immunity Cycle by Integrating Lipid Nanoparticle-mRNA Formulations and Dendritic Cell Therapy,” Nature Nanotechnology 18, no. 11 (2023): 1364–1374.

[53] A. S. Thatte, A. G. Hamilton, B. E. Nachod, et al., “mRNA Lipid Nanoparticles for Ex Vivo Engineering of Immunosuppressive T Cells for Autoimmunity Therapies,” Nano Letters 23, no. 22 (2023): 10179–10188.

[54] E. H. Kim, S. V. Teerdhala, and M. S. Padilla, “Lipid Nanoparticle-mediated RNA Delivery for Immune Cell Modulation,” European Journal of Immunology 54, no. 12 (2024): e2451008.

[55] J. Y. Ko, C. H. Park, H. C. Koh, et al., “Human Embryonic Stem Cell-derived Neural Precursors as a Continuous, Stable, and on-demand Source for human Dopamine Neurons,” Journal of Neurochemistry 103, no. 4 (2007): 1417–1429.

[56] S. M. Kim, M. S. Lim, and E. H. Lee, “Efficient Generation of Dopamine Neurons by Synthetic Transcription Factor mRNAs,” Molecular Therapy 25, no. 9 (2017): 2028–2037.

[57] G. Basha, A. G. Cottle, and T. Pretheeban, “Lipid Nanoparticle-mediated Silencing of Osteogenic Suppressor GNAS Leads to Osteogenic Differentiation of Mesenchymal Stem Cells in Vivo,” Molecular Therapy 30, no. 9 (2022): 3034–3051.

[58] T. Wei, Q. Cheng, L. Farbiak, et al., “Delivery of Tissue-Targeted Scalpels: Opportunities and Challenges for in Vivo CRISPR/Cas-Based Genome Editing,” ACS Nano 14, no. 8 (2020): 9243–9262.

[59] G. Schwank, B. K. Koo, V. Sasselli, et al., “Functional Repair of CFTR by CRISPR/Cas9 in Intestinal Stem Cell Organoids of Cystic Fibrosis Patients,” Cell Stem Cell 13, no. 6 (2013): 653–658.

[60] J. Drost, R. van Boxtel, F. Blokzijl, et al., “Use of CRISPR-modified human Stem Cell Organoids to Study the Origin of Mutational Signatures in Cancer,” Science 358, no. 6360 (2017): 234–238.

[61] H. Zhang, H. Jiang, W. Xie, et al., “LNPs-mediated VEGF-C mRNA Delivery Promotes Heart Repair and Attenuates Inflammation by Stimulating Lymphangiogenesis Post-myocardial Infarction,” Biomaterials 322 (2025): 123410.

[62] I. Sahu, A. Haque, B. Weidensee, et al., “Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases,” Molecular Therapy 27, no. 4 (2019): 803–823.

[63] A. Magadum, K. Kaur, and L. Zangi, “mRNA-Based Protein Replacement Therapy for the Heart,” Molecular Therapy 27, no. 4 (2019): 785–793.

[64] Z. Trepotec, E. Lichtenegger, C. Plank, et al., “Delivery of mRNA Therapeutics for the Treatment of Hepatic Diseases,” Molecular Therapy 27, no. 4 (2019): 794–802.

[65] C. Liu, Q. Shi, X. Huang, et al., “mRNA-based Cancer Therapeutics,” Nature Reviews Cancer 23, no. 8 (2023): 526–543.

[66] P. Berraondo, P. G. V. Martini, M. A. Avila, et al., “Messenger RNA Therapy for Rare Genetic Metabolic Diseases,” Gut 68, no. 7 (2019): 1323–1330.

[67] S. Uchida, K. Itaka, H. Uchida, et al., “Messenger RNA Introduction Into the Central Nervous System Using Polyplex Nanomicelle,” PLoS ONE 8, no. 2 (2013): e56220.

[68] Z. S. Badieyan, T. Berezhanskyy, M. Utzinger, et al., “Transcript-activated Collagen Matrix as Sustained mRNA Delivery System for Bone Regeneration,” J Control Release 239 (2016): 137–148.

[69] V. Anttila, A. Saraste, J. Knuuti, et al., “Direct Intramyocardial Injection of VEGF mRNA in Patients Undergoing Coronary Artery Bypass Grafting,” Molecular Therapy 31, no. 3 (2023): 866–874.

[70] L. M. Gan, M. Lagerstrom-Fermer, and L. G. Carlsson, “Intradermal Delivery of Modified mRNA Encoding VEGF-A in Patients With Type 2 Diabetes,” Nature Communications 10, no. 1 (2019): 871.

[71] S. M. Rowe, J. B. Zuckerman, D. Dorgan, et al., “Inhaled mRNA Therapy for Treatment of Cystic Fibrosis: Interim Results of a Randomized, Double-blind, Placebo-controlled Phase 1/2 Clinical Study,” Journal of Cystic Fibrosis 22, no. 4 (2023): 656–664.

[72] D. Koeberl, A. Schulze, N. Sondheimer, et al., “Interim Analyses of a First-in-human Phase 1/2 mRNA Trial for Propionic Acidaemia,” Nature 628, no. 8009 (2024): 872–877.

[73] N. Bangel-Ruland, K. Tomczak, and E. Fernandez Fernandez, “Cystic Fibrosis Transmembrane Conductance Regulator-mRNA Delivery: A Novel Alternative for Cystic Fibrosis Gene Therapy,” The Journal of Gene Medicine 15, no. 11-12 (2013): 414–426.

[74] E. Robinson, K. D. MacDonald, K. Slaughter, et al., “Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis,” Molecular Therapy 26, no. 8 (2018): 2034–2046.

[75] S. Ramaswamy, N. Tonnu, K. Tachikawa, et al., “Systemic Delivery of Factor IX Messenger RNA for Protein Replacement Therapy,” PNAS 114, no. 10: E1941–E50.

[76] J. Russick, S. Delignat, P. Milanov, et al., “Correction of Bleeding in Experimental Severe Hemophilia A by Systemic Delivery of Factor VIII-encoding mRNA,” Haematologica 105, no. 4 (2020): 1129–1137.

[77] Q. Cheng, T. Wei, Y. Jia, et al., “Dendrimer-Based Lipid Nanoparticles Deliver Therapeutic FAH mRNA to Normalize Liver Function and Extend Survival in a Mouse Model of Hepatorenal Tyrosinemia Type I,” Advanced Materials 30, no. 52 (2018): e1805308.

[78] L. Jiang, P. Berraondo, D. Jerico, et al., “Systemic Messenger RNA as an Etiological Treatment for Acute Intermittent Porphyria,” Nature Medicine 24, no. 12 (2018): 1899–1909.

[79] D. An, J. L. Schneller, A. Frassetto, et al., “Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia,” Cell reports 21, no. 12 (2017): 3548–3558.

[80] F. DeRosa, L. Smith, Y. Shen, et al., “Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy,” Molecular Therapy 27, no. 4 (2019): 878–889.

[81] A. Karadagi, A. G. Cavedon, H. Zemack, et al., “Systemic Modified Messenger RNA for Replacement Therapy in Alpha 1-antitrypsin Deficiency,” Scientific Reports 10, no. 1 (2020): 7052.

[82] M. A. Islam, Y. Xu, W. Tao, et al., “Author Correction: Restoration of Tumour-growth Suppression in Vivo via Systemic Nanoparticle-mediated Delivery of PTEN mRNA,” Nat Biomed Eng 2, no. 12 (2018): 968.

[83] N. Kong, W. Tao, X. Ling, et al., “Synthetic mRNA Nanoparticle-mediated Restoration of p53 Tumor Suppressor Sensitizes p53-deficient Cancers to mTOR inhibition,” Science Translational Medicine no. 523 (2019): eaaw1565.

[84] R. Zhang, K. Men, X. Zhang, et al., “Delivery of a Modified mRNA Encoding IL-22 Binding Protein (IL-22BP) for Colon Cancer Gene Therapy,” Journal of Biomedical Nanotechnology 14, no. 7 (2018): 1239–1251.

[85] M. H. Porteus, “A New Class of Medicines Through DNA Editing,” New England Journal of Medicine 380, no. 10 (2019): 947–959.

[86] D. Wang, F. Zhang, and G. Gao, “CRISPR-based Therapeutic Genome Editing: Strategies and in Vivo Delivery by AAV Vectors,” Cell 181, no. 1 (2020): 136–150.

[87] S. Ferrari, V. Vavassori, D. Canarutto, et al., “Gene Editing of Hematopoietic Stem Cells: Hopes and Hurdles Toward Clinical Translation,” Frontiers in Genome Editing 3 (2021): 618378.

[88] A. Raguram, S. Banskota, and D. R. Liu, “Therapeutic in Vivo Delivery of Gene Editing Agents,” Cell 185, no. 15 (2022): 2806–2827.

[89] L. Breda, T. E. Papp, and M. P. Triebwasser, “In vivo Hematopoietic Stem Cell Modification by mRNA Delivery,” Science 381, no. 6656 (2023): 436–443, https://doi.org/10.1126/science.ade6967.

[90] J. D. Gillmore, E. Gane, J. Taubel, et al., “CRISPR-Cas9 in Vivo Gene Editing for Transthyretin Amyloidosis,” New England Journal of Medicine 385, no. 6 (2021): 493–502.

[91] H. J. Longhurst, K. Lindsay, and R. S. Petersen, “CRISPR-Cas9 in Vivo Gene Editing of KLKB1 for Hereditary Angioedema,” New England Journal of Medicine 390, no. 5 (2024): 432–441.

[92] H. Wang, Y. Yang, J. Liu, et al., “Direct Cell Reprogramming: Approaches, Mechanisms and Progress,” Nature Reviews Molecular Cell Biology 22, no. 6 (2021): 410–424.

[93] K. Song, Y. J. Nam, X. Luo, et al., “Heart Repair by Reprogramming Non-myocytes With Cardiac Transcription Factors,” Nature 485, no. 7400 (2012): 599–604.

[94] O. Chabanovska, A. M. Galow, R. David, et al., “mRNA—A Game Changer in Regenerative Medicine, Cell-based Therapy and Reprogramming Strategies,” Advanced Drug Delivery Reviews 179 (2021): 114002.

[95] L. Breda, T. E. Papp, M. P. Triebwasser, et al., “In Vivo Hematopoietic Stem Cell Modification by mRNA Delivery,” Science 381, no. 6656 (2023): 436–443.

[96] C. Y. Lin, S. T. Crowley, S. Uchida, et al., “Treatment of Intervertebral Disk Disease by the Administration of mRNA Encoding a Cartilage-Anabolic Transcription Factor,” Mol Ther Nucleic Acids 16 (2019): 162–171.

[97] T. Yang, M. Poenisch, R. Khanal, et al., “Therapeutic HNF4A mRNA Attenuates Liver Fibrosis in a Preclinical Model,” Journal of Hepatology 75, no. 6 (2021): 1420–1433.

[98] F. Rizvi, Y. R. Lee, R. Diaz-Aragon, et al., “VEGFA mRNA-LNP Promotes Biliary Epithelial Cell-to-hepatocyte Conversion in Acute and Chronic Liver Diseases and Reverses Steatosis and Fibrosis,” BioRxiv (2023).

[99] F. Rizvi, E. Everton, A. R. Smith, et al., “Author Correction: Murine Liver Repair via Transient Activation of Regenerative Pathways in Hepatocytes Using Lipid Nanoparticle-complexed Nucleoside-modified mRNA,” Nature Communications 12, no. 1 (2021): 2825.

[100] V. Anttila, A. Saraste, J. Knuuti, et al., “Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial,” Mol Ther Methods Clin Dev 18 (2020): 464–472.

[101] N. Sun, B. Ning, K. M. Hansson, et al., “Modified VEGF-A mRNA Induces Sustained Multifaceted Microvascular Response and Accelerates Diabetic Wound Healing,” Scientific Reports 8, no. 1 (2018): 17509.

[102] L. Carlsson, J. C. Clarke, and C. Yen, “Biocompatible, Purified VEGF-A mRNA Improves Cardiac Function After Intracardiac Injection 1 Week Post-myocardial Infarction in Swine,” Mol Ther Methods Clin Dev 9 (2018): 330–346.

[103] G. Zhao, L. Xue, A. I. Weiner, et al., “TGF-βR2 Signaling Coordinates Pulmonary Vascular Repair After Viral Injury in Mice and human Tissue,” Science Translational Medicine 16, no. 732 (2024): eadg6229.

[104] Y. Fukushima, S. Uchida, H. Imai, et al., “Treatment of Ischemic Neuronal Death by Introducing Brain-derived Neurotrophic Factor mRNA Using Polyplex Nanomicelle,” Biomaterials 270 (2021): 120681.

[105] E. R. Balmayor, J. P. Geiger, and M. K. Aneja, “Chemically Modified RNA Induces Osteogenesis of Stem Cells and human Tissue Explants as Well as Accelerates Bone Healing in Rats,” Biomaterials 87 (2016): 131–146.

[106] S. Elangovan, B. Khorsand, and A. V. Do, “Chemically Modified RNA Activated Matrices Enhance Bone Regeneration,” J Control Release 218 (2015): 22–28.

[107] Y. He, A. P. R. Johnston, and C. W. Pouton, “Therapeutic Applications of Cell Engineering Using mRNA Technology,” Trends in Biotechnology 43, no. 1 (2024): 83–97.

[108] R. Trokovic, J. Weltner, P. Noisa, et al., “Combined Negative Effect of Donor Age and Time in Culture on the Reprogramming Efficiency Into Induced Pluripotent Stem Cells,” Stem Cell Research 15, no. 1 (2015): 254–262.

[109] W. Ferguson and G. A. Erikson, “Influence of Donor Age on Induced Pluripotent Stem Cells,” Nature Biotechnology 35, no. 1 (2017): 69–74.

[110] T. T. Smith, S. B. Stephan, and H. F. Moffett, “In Situ Programming of Leukaemia-specific T Cells Using Synthetic DNA Nanocarriers,” Nature Nanotechnology 12, no. 8 (2017): 813–820.

[111] N. N. Parayath, S. B. Stephan, and A. L. Koehne, “In Vitro-transcribed Antigen Receptor mRNA Nanocarriers for Transient Expression in Circulating T Cells in Vivo,” Nature Communications 11, no. 1 (2020): 6080.

[112] J. G. Rurik, I. Tombacz, A. Yadegari, et al., “CAR T Cells Produced in Vivo to Treat Cardiac Injury,” Science 375, no. 6576 (2022): 91–96.

[113] I. Tombacz, D. Laczko, H. Shahnawaz, et al., “Highly Efficient CD4+ T Cell Targeting and Genetic Recombination Using Engineered CD4+ Cell-homing mRNA-LNPs,” Molecular Therapy 29, no. 11 (2021): 3293–3304.

[114] A. Kheirolomoom, A. J. Kare, E. S. Ingham, et al., “In Situ T-cell Transfection by Anti-CD3-conjugated Lipid Nanoparticles Leads to T-cell Activation, Migration, and Phenotypic Shift,” Biomaterials 281 (2022): 121339.

[115] J. E. Zhou, L. Sun, Y. Jia, et al., “Lipid Nanoparticles Produce Chimeric Antigen Receptor T Cells With Interleukin-6 Knockdown in Vivo,” J Control Release 350 (2022): 298–307.

[116] C. Chen, W. Jing, Y. Chen, et al., “Intracavity Generation of Glioma Stem Cell-specific CAR Macrophages Primes Locoregional Immunity for Postoperative Glioblastoma Therapy,” Science Translational Medicine 14, no. 656 (2022): eabn1128.

[117] Y. Liu, W. Q. Jing, J. Zhang, et al., “In Situ MUC1-specific CAR Engineering of Tumor-supportive Macrophages Stimulates Tumoricidal Immunity Against Pancreatic Adenocarcinoma,” Nano Today 49 (2023): 101805.

[118] J. G. Rurik, I. Tombácz, A. Yadegari, et al., “CAR T Cells Produced in Vivo to Treat Cardiac Injury,” Science 375, no. 6576 (2022): 91–96.

[119] A. G. Hamilton, K. L. Swingle, and R. A. Joseph, “Ionizable Lipid Nanoparticles With Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering,” Adv Healthc Mater 12, no. 30 (2023): e2301515.

[120] V. Granit, M. Benatar, and M. Kurtoglu, “Safety and Clinical Activity of Autologous RNA Chimeric Antigen Receptor T-cell Therapy in myasthenia gravis (MG-001): A Prospective, Multicentre, Open-label, Non-randomised Phase 1b/2a Study (vol 22, pg 578, 2023),” Lancet Neurology 22, no. 9 (2023): E10–E.

[121] C. Tang, W. Jing, K. Han, et al., “mRNA-Laden Lipid-Nanoparticle-Enabled in Situ CAR-Macrophage Engineering for the Eradication of Multidrug-Resistant Bacteria in a Sepsis Mouse Model,” ACS Nano 18, no. 3 (2024): 2261–2278.

[122] A. J. Mukalel, A. G. Hamilton, M. M. Billingsley, et al., “Oxidized mRNA Lipid Nanoparticles for in Situ Chimeric Antigen Receptor Monocyte Engineering,” Advanced Functional Materials 34, no. 27 (2024): 2312038.

[123] Z. Liu, C. Chen, Y. Zhang, et al., “Legumain in Situ Engineering Promotes Efferocytosis of CAR Macrophage to Treat Cardiac Fibrosis,” Advanced Materials 37, no. 27 (2025): e2417831.

[124] V. Francia, Y. Zhang, M. H. Y. Cheng, et al., “A Magnetic Separation Method for Isolating and Characterizing the Biomolecular Corona of Lipid Nanoparticles,” PNAS 121, no. 11 (2024): e2307803120.

[125] K. Son, M. Ueda, K. Taguchi, et al., “Evasion of the Accelerated Blood Clearance Phenomenon by Polysarcosine Coating of Liposomes,” J Control Release 322 (2020): 209–216.

[126] H. Kim, R. Zenhausern, K. Gentry, et al., “Lipid Nanoparticle-mediated mRNA Delivery to CD34(+) Cells in rhesus Monkeys,” Nature Biotechnology 43, no. 11 (2024): 1813–1820.

[127] N. Chaudhary, D. Weissman, and K. A. Whitehead, “mRNA Vaccines for Infectious Diseases: Principles, Delivery and Clinical Translation,” Nature Reviews Drug Discovery 20, no. 11 (2021): 817–838.

[128] M.-W. Ku, P. Charneau, and L. Majlessi, “Use of Lentiviral Vectors in Vaccination,” Expert Review of Vaccines 20, no. 12 (2021): 1571–1586.

[129] J. Di, Z. Du, K. Wu, et al., “Biodistribution and Non-linear Gene Expression of mRNA LNPs Affected by Delivery Route and Particle Size,” Pharmaceutical Research 39, no. 1 (2022): 105–114.

[130] S. M. Moghimi, A. C. Hunter, and J. C. Murray, “Long-circulating and Target-specific Nanoparticles: Theory to Practice,” Pharmacological reviews 53, no. 2 (2001): 283–318.

[131] H. Y. Park, P. S. Tan, R. Kavishna, et al., “Enhancing Vaccine Antibody Responses by Targeting Clec9A on Dendritic Cells,” NPJ Vaccines 2 (2017): 31.

[132] C. Macri, D. Jenika, C. Ouslinis, et al., “Targeting Dendritic Cells to Advance Cross-presentation and Vaccination Outcomes,” Seminars in Immunology 68 (2023): 101762.

[133] P. Stoitzner, N. Romani, C. Rademacher, et al., “Antigen Targeting to Dendritic Cells: Still a Place in Future Immunotherapy?,” European Journal of Immunology 52, no. 12 (2022): 1909–1924.

[134] D. Yin, Y. Zhong, S. Ling, et al., “Dendritic-cell-targeting Virus-Like Particles as Potent mRNA Vaccine Carriers,” Nat Biomed Eng 9, no. 2 (2024): 185–200.

[135] J. Kim, Y. Eygeris, and R. C. Ryals, “Strategies for Non-viral Vectors Targeting Organs Beyond the Liver,” Nature Nanotechnology 19, no. 4 (2024): 428–447.

[136] R. Daneman and A. Prat, “The Blood-brain Barrier,” Cold Spring Harbor perspectives in biology 7, no. 1 (2015): a020412.

[137] S. A. Dilliard, Q. Cheng, and D. J. Siegwart, “On the Mechanism of Tissue-specific mRNA Delivery by Selective Organ Targeting Nanoparticles,” PNAS 118, no. 52 (2021): e2109256118.

[138] Q. Cheng, T. Wei, L. Farbiak, et al., “Selective Organ Targeting (SORT) Nanoparticles for Tissue-specific mRNA Delivery and CRISPR-Cas Gene Editing,” Nature Nanotechnology 15, no. 4 (2020): 313–320.

[139] S. A. Dilliard and S. D. J. Passive, “active and Endogenous Organ-targeted Lipid and Polymer Nanoparticles for Delivery of Genetic Drugs,” Nature Reviews Materials 8, no. 4 (2023): 282–300.

[140] J. Witten, Y. Hu, R. Langer, et al., “Recent Advances in Nanoparticulate RNA Delivery Systems,” PNAS 121, no. 11 (2024): e2307798120.

[141] N. S. Kola, D. Patel, and A. Thakur, “RNA-Based Vaccines and Therapeutics against Intracellular Pathogens,” Methods in Molecular Biology 2813 (2024): 321–370.

[142] A. K. Patel, J. C. Kaczmarek, and S. Bose, “Inhaled Nanoformulated mRNA Polyplexes for Protein Production in Lung Epithelium,” Advanced Materials 31, no. 8 (2019): e1805116.

[143] X. Su, J. Fricke, D. G. Kavanagh, et al., “In Vitro and in Vivo mRNA Delivery Using Lipid-enveloped pH-responsive Polymer Nanoparticles,” Mol Pharm 8, no. 3 (2011): 774–787.

[144] E. Alton, D. K. Armstrong, and D. Ashby, “Repeated Nebulisation of Non-viral CFTR Gene Therapy in Patients With Cystic Fibrosis: A Randomised, Double-blind, Placebo-controlled, Phase 2b Trial,” Lancet Respir Med 3, no. 9 (2015): 684–691.

[145] M. P. Lokugamage, D. Vanover, J. Beyersdorf, et al., “Optimization of Lipid Nanoparticles for the Delivery of Nebulized Therapeutic mRNA to the Lungs,” Nat Biomed Eng 5, no. 9 (2021): 1059–1068.

[146] J. Kim, A. Jozic, Y. Lin, et al., “Engineering Lipid Nanoparticles for Enhanced Intracellular Delivery of mRNA Through Inhalation,” ACS Nano 16, no. 9 (2022): 14792–14806.

[147] Y. He, Y. Liang, R. Han, et al., “Rational Particle Design to Overcome Pulmonary Barriers for Obstructive Lung Diseases Therapy,” J Control Release 314 (2019): 48–61.

[148] A. Y. Jiang, J. Witten, and I. O. Raji, “Combinatorial Development of Nebulized mRNA Delivery Formulations for the Lungs,” Nature Nanotechnology 19, no. 3 (2024): 364–375.

[149] S. Gharse and J. Fiegel, “Large Porous Hollow Particles: Lightweight Champions of Pulmonary Drug Delivery,” Current Pharmaceutical Design 22, no. 17 (2016): 2463–2469.

[150] J. Witten, I. Raji, and R. S. Manan, “Artificial Intelligence-guided Design of Lipid Nanoparticles for Pulmonary Gene Therapy,” Nature Biotechnology 43, no. 11 (2024): 1790–1799.

[151] N. Tsapis, D. Bennett, B. Jackson, et al., “Trojan Particles: Large Porous Carriers of Nanoparticles for Drug Delivery,” PNAS 99, no. 19 (2002): 12001–12005.

[152] A. R. Huang, M. M. Pressnall, and R. L. Lu, “Human Intratumoral Therapy: Linking Drug Properties and Tumor Transport of Drugs in Clinical Trials,” J Control Release 326 (2020): 203–221.

[153] S. L. Hewitt, D. Bailey, J. Zielinski, et al., “Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment,” Clinical Cancer Research 26, no. 23 (2020): 6284–6298.

[154] Y. Li, Z. Su, W. Zhao, et al., “Multifunctional Oncolytic Nanoparticles Deliver Self-replicating IL-12 RNA to Eliminate Established Tumors and Prime Systemic Immunity,” Nat Cancer 1, no. 9 (2020): 882–893.

[155] S. L. Hewitt, A. Bai, D. Bailey, et al., “Durable Anticancer Immunity From Intratumoral Administration of IL-23, IL-36γ, and OX40L mRNAs,” Science Translational Medicine 11, no. 477 (2019): eaat9143.

[156] D. Rosenblum, A. Gutkin, R. Kedmi, et al., “CRISPR-Cas9 Genome Editing Using Targeted Lipid Nanoparticles for Cancer Therapy,” Science Advances 6, no. 47 (2020): eabc9450.

[157] D. Zhang, G. X. Wang, X. L. Yu, et al., “Enhancing CRISPR/Cas Gene Editing Through Modulating Cellular Mechanical Properties for Cancer Therapy,” Nature Nanotechnology 17, no. 7 (2022): 777–787.

[158] L. Bejarano, M. J. C. Jordao, and J. A. Joyce, “Therapeutic Targeting of the Tumor Microenvironment,” Cancer discovery 11, no. 4 (2021): 933–959.

[159] S. Patel, R. C. Ryals, and K. K. Weller, “Lipid Nanoparticles for Delivery of Messenger RNA to the Back of the Eye,” J Control Release 303 (2019): 91–100.

[160] T. Zhou, C. He, P. Lai, et al., “miR-204-containing Exosomes Ameliorate GVHD-associated Dry Eye Disease,” Science Advances 8, no. 2 (2022): eabj9617.

[161] I. C. Turnbull, A. A. Eltoukhy, and K. M. Fish, “Myocardial Delivery of Lipidoid Nanoparticle Carrying modRNA Induces Rapid and Transient Expression,” Molecular Therapy 24, no. 1 (2016): 66–75.

[162] R. D. Singh, M. L. Hillestad, and C. Livia, “M(3)RNA Drives Targeted Gene Delivery in Acute Myocardial Infarction,” Tissue Engineering Part A 25, no. 1-2 (2019): 145–158.

[163] J. F. Nabhan, K. M. Wood, V. P. Rao, et al., “Intrathecal Delivery of Frataxin mRNA Encapsulated in Lipid Nanoparticles to Dorsal Root Ganglia as a Potential Therapeutic for Friedreich's Ataxia,” Sci Rep-Uk 6 (2016): 20019.

[164] Y. Eygeris, M. Gupta, J. Kim, et al., “Chemistry of Lipid Nanoparticles for RNA Delivery,” Accounts of Chemical Research 55, no. 1 (2022): 2–12.

[165] F. Sebastiani, M. Yanez Arteta, and M. Lerche, “Apolipoprotein E Binding Drives Structural and Compositional Rearrangement of mRNA-Containing Lipid Nanoparticles,” ACS Nano 15, no. 4 (2021): 6709–6722.

[166] M. Neagu, Z. Piperigkou, K. Karamanou, et al., “Protein Bio-corona: Critical Issue in Immune Nanotoxicology,” Archives of Toxicology 91, no. 3 (2017): 1031–1048.

[167] C. C. Fleischer and C. K. Payne, “Nanoparticle-cell Interactions: Molecular Structure of the Protein Corona and Cellular Outcomes,” Accounts of Chemical Research 47, no. 8 (2014): 2651–2659.

[168] K. E. Wheeler, A. J. Chetwynd, K. M. Fahy, et al., “Environmental Dimensions of the Protein Corona,” Nature Nanotechnology 16, no. 6 (2021): 617–629.

[169] V. Francia, R. M. Schiffelers, and P. R. Cullis, “The Biomolecular Corona of Lipid Nanoparticles for Gene Therapy,” Bioconjugate Chem 31, no. 9 (2020): 2046–2059.

[170] D. Song and Q. Xu, “Engineering a Nano/Biointerface for Cell and Organ-Selective Drug Delivery,” Langmuir 38, no. 30 (2022): 9092–9098.

[171] J. Y. Oh, H. S. Kim, L. Palanikumar, et al., “Cloaking Nanoparticles With Protein Corona Shield for Targeted Drug Delivery,” Nature Communications 9, no. 1 (2018): 4548.

[172] M. Mahmoudi, I. Lynch, M. R. Ejtehadi, et al., “Protein-nanoparticle Interactions: Opportunities and Challenges,” Chem Rev 111, no. 9 (2011): 5610–5637.

[173] M. Qiu, Y. Tang, J. Chen, et al., “Lung-selective mRNA Delivery of Synthetic Lipid Nanoparticles for the Treatment of Pulmonary Lymphangioleiomyomatosis,” PNAS 119, no. 8 (2022): e2116271119.

[174] F. Ma, L. Yang, Z. Sun, et al., “Neurotransmitter-derived Lipidoids (NT-lipidoids) for Enhanced Brain Delivery Through Intravenous Injection,” Science Advances 6, no. 30 (2020): eabb4429.

[175] W. Cai, T. Luo, X. Chen, et al., “A Combinatorial Library of Biodegradable Lipid Nanoparticles Preferentially Deliver mRNA Into Tumor Cells to Block Mutant RAS Signaling,” Advanced Functional Materials 32, no. 41 (2022): 2204947.

[176] L. Xue, N. Gong, S. J. Shepherd, et al., “Rational Design of Bisphosphonate Lipid-Like Materials for mRNA Delivery to the Bone Microenvironment,” Journal of the American Chemical Society 144, no. 22 (2022): 9926–9937.

[177] L. Miao, L. Li, Y. Huang, et al., “Delivery of mRNA Vaccines With Heterocyclic Lipids Increases Anti-tumor Efficacy by STING-mediated Immune Cell Activation,” Nature Biotechnology 37, no. 10 (2019): 1174–1185.

[178] T. Cedervall, I. Lynch, S. Lindman, et al., “Understanding the Nanoparticle-protein Corona Using Methods to Quantify Exchange Rates and Affinities of Proteins for Nanoparticles,” PNAS 104, no. 7 (2007): 2050–2055.

[179] R. Garcia-Alvarez, M. Hadjidemetriou, A. Sanchez-Iglesias, et al., “In Vivo Formation of Protein Corona on Gold Nanoparticles. The Effect of Their Size and Shape,” Nanoscale 10, no. 3 (2018): 1256–1264.

[180] R. M. Williams, J. Shah, and B. D. Ng, “Mesoscale Nanoparticles Selectively Target the Renal Proximal Tubule Epithelium,” Nano Letters 15, no. 4 (2015): 2358–2364.

[181] R. M. Williams, J. Shah, and H. S. Tian, “Selective Nanoparticle Targeting of the Renal Tubules,” Hypertension 71, no. 1 (2018): 87–94.

[182] J. Y. Park, S. Park, T. S. Lee, et al., “Biodegradable Micro-sized Discoidal Polymeric Particles for Lung-targeted Delivery System,” Biomaterials 218 (2019): 119331.

[183] X. Lin, J. He, W. Li, et al., “Lung-Targeting Lysostaphin Microspheres for Methicillin-Resistant Staphylococcus aureus Pneumonia Treatment and Prevention,” ACS Nano 15, no. 10 (2021): 16625–16641.

[184] Y. Lin, Q. Cheng, and T. Wei, “Surface Engineering of Lipid Nanoparticles: Targeted Nucleic Acid Delivery and Beyond,” Biophys Rep 9, no. 5 (2023): 255–278.

[185] Z. B. Akkuş-Dağdeviren, S. Arısoy, and J. D. Friedl, “Polyphosphate Coated Nanoparticles: Enzyme-activated Charge-reversal Gene Delivery Systems,” International Journal of Pharmaceutics 646 (2023): 123474.

[186] S. Renzi, L. Digiacomo, D. Pozzi, et al., “Structuring Lipid Nanoparticles, DNA, and Protein Corona Into Stealth Bionanoarchitectures for in Vivo Gene Delivery,” Nature Communications 15, no. 1 (2024): 9119.

[187] M. Fernández, F. Javaid, and V. Chudasama, “Advances in Targeting the Folate Receptor in the Treatment/Imaging of Cancers,” Chemical Science 9, no. 4 (2018): 790–810.

[188] M. Herrera-Barrera, R. C. Ryals, and M. Gautam, “Peptide-guided Lipid Nanoparticles Deliver mRNA to the Neural Retina of Rodents and Nonhuman Primates,” Science Advances 9, no. 2 (2023): eadd4623.

[189] D. Wang, Y. Sun, Y. Liu, et al., “Clinical Translation of Immunoliposomes for Cancer Therapy: Recent Perspectives,” Expert Opin Drug Deliv 15, no. 9 (2018): 893–903.

[190] E. Kon, N. Ad-El, I. Hazan-Halevy, et al., “Targeting Cancer With mRNA-lipid Nanoparticles: Key Considerations and Future Prospects,” Nature reviews Clinical oncology 20, no. 11 (2023): 739–754.

[191] L. Huang, Z. Huang, Y. Zhang, et al., “Advances in Targeted Delivery of mRNA Into Immune Cells for Enhanced Cancer Therapy,” Theranostics 14, no. 14 (2024): 5528–5550.

[192] N. Veiga, M. Goldsmith, Y. Granot, et al., “Cell Specific Delivery of Modified mRNA Expressing Therapeutic Proteins to Leukocytes,” Nature Communications 9, no. 1 (2018): 4493.

[193] C. Li, A. Georgakopoulou, G. A. Newby, et al., “In Vivo HSC Prime Editing Rescues Sickle Cell Disease in a Mouse Model,” Blood 141, no. 17 (2023): 2085–2099.

[194] S. L. Hayward, C. L. Wilson, and S. Kidambi, “Hyaluronic Acid-conjugated Liposome Nanoparticles for Targeted Delivery to CD44 Overexpressing Glioblastoma Cells,” Oncotarget 7, no. 23 (2016): 34158–34171.

[195] Z. Tang, X. You, Y. Xiao, et al., “Inhaled mRNA Nanoparticles Dual-targeting Cancer Cells and Macrophages in the Lung for Effective Transfection,” PNAS 120, no. 44 (2023): e2304966120.

[196] K. N. Sugahara, T. Teesalu, P. P. Karmali, et al., “Tissue-Penetrating Delivery of Compounds and Nanoparticles Into Tumors,” Cancer Cell 16, no. 6 (2009): 510–520.

[197] L. Alberici, L. Roth, K. N. Sugahara, et al., “De Novo Design of a Tumor-penetrating Peptide,” Cancer Research 73, no. 2 (2013): 804–812.

[198] P. Scodeller, L. Simon-Gracia, S. Kopanchuk, et al., “Precision Targeting of Tumor Macrophages With a CD206 Binding Peptide,” Scientific Reports 7, no. 1 (2017): 14655.

[199] A. M. Sofias, Y. C. Toner, and A. E. Meerwaldt, “Tumor Targeting by Αβ-Integrin-Specific Lipid Nanoparticles Occurs Phagocyte Hitchhiking,” Acs Nano 14, no. 7 (2020): 7832–7846.

[200] M. Kang, S. H. Lee, M. Kwon, et al., “Nanocomplex-Mediated in Vivo Programming to Chimeric Antigen Receptor-M1 Macrophages for Cancer Therapy,” Advanced Materials 33, no. 43 (2021): e2103258.

[201] L. Zheng, H. Wu, N. Wen, et al., “Aptamer-Functionalized Nanovaccines: Targeting in Vivo DC Subsets for Enhanced Antitumor Immunity,” ACS Appl Mater Interfaces 15, no. 15 (2023): 18590–18597.

[202] J. Sam Lee, M. Kim, and H. Jin, “DNA Aptamer-conjugated Lipid Nanoparticle for Targeted PTEN mRNA Delivery to Prostate Cancer Cells,” International Journal of Pharmaceutics 662 (2024): 124519.

[203] A. J. Sinegra, M. Evangelopoulos, J. Park, et al., “Lipid Nanoparticle Spherical Nucleic Acids for Intracellular DNA and RNA Delivery,” Nano Letters 21, no. 15 (2021): 6584–6591.

[204] C. D. Sago, M. P. Lokugamage, D. Loughrey, et al., “Augmented Lipid-nanoparticle-mediated in Vivo Genome Editing in the Lungs and Spleen by Disrupting Cas9 Activity in the Liver,” Nat Biomed Eng 6, no. 2 (2022): 157–167.

[205] S. Kameda, H. Ohno, and H. Saito, “Synthetic Circular RNA Switches and Circuits That Control Protein Expression in Mammalian Cells,” Nucleic Acids Res 51, no. 4 (2023): e24.

[206] R. Jain, J. P. Frederick, E. Y. Huang, et al., “MicroRNAs Enable mRNA Therapeutics to Selectively Program Cancer Cells to Self-Destruct,” Nucleic acid therapeutics 28, no. 5 (2018): 285–296.

[207] M. Żak, J. Yoo, and L. Zangi, “Therapeutic Potential of Systemically Delivered Breast Cancer Specific Modified mRNA,” European Journal of Cancer 174 (2022): S102.

[208] Y. Fei, X. Yu, P. Liu, et al., “Simplified Lipid Nanoparticles for Tissue- And Cell-Targeted mRNA Delivery Facilitate Precision Tumor Therapy in a Lung Metastasis Mouse Model,” Advanced Materials (2024): e2409812.

[209] A. A. Green, P. A. Silver, J. J. Collins, et al., “Toehold Switches: De-novo-designed Regulators of Gene Expression,” Cell 159, no. 4 (2014): 925–939.

[210] E. M. Zhao, A. S. Mao, H. de Puig, et al., “RNA-responsive Elements for Eukaryotic Translational Control,” Nature Biotechnology 40, no. 4 (2022): 539–545.

[211] K. A. Dittmar, J. M. Goodenbour, and T. Pan, “Tissue-specific Differences in human Transfer RNA Expression,” PLoS genetics 2, no. 12 (2006): e221.

[212] J. B. Plotkin, H. Robins, and A. J. Levine, “Tissue-specific Codon Usage and the Expression of human Genes,” Proceedings of the National Academy of Sciences 101, no. 34 (2004): 12588–12591.

[213] D. Chu, E. Kazana, N. Bellanger, et al., “Translation Elongation Can Control Translation Initiation on Eukaryotic mRNA s,” The EMBO journal 33, no. 1 (2014): 21–34.

[214] K. Karikó, H. Ni, J. Capodici, et al., “mRNA Is an Endogenous Ligand for Toll-Like Receptor 3,” Journal of Biological Chemistry 279, no. 13 (2004): 12542–12550.

[215] M. Tatematsu, K. Funami, T. Seya, et al., “Extracellular RNA Sensing by Pattern Recognition Receptors,” J Innate Immun 10, no. 5-6 (2018): 398–406.

[216] G. Frega, Q. Wu, and J. Le Naour, “Trial Watch: Experimental TLR7/TLR8 Agonists for Oncological Indications,” Oncoimmunology 9, no. 1 (2020): 1796002.

[217] B. R. Anderson, H. Muramatsu, B. K. Jha, et al., “Nucleoside Modifications in RNA Limit Activation of 2'-5'-oligoadenylate Synthetase and Increase Resistance to Cleavage by RNase L,” Nucleic Acids Res 39, no. 21 (2011): 9329–9338.

[218] S. Ndeupen, Z. Qin, S. Jacobsen, et al., “The mRNA-LNP Platform's Lipid Nanoparticle Component Used in Preclinical Vaccine Studies Is Highly Inflammatory,” Iscience 24, no. 12 (2021): 103479.

[219] S. M. Moghimi and D. Simberg, “Pro-inflammatory Concerns With Lipid Nanoparticles,” Molecular Therapy 30, no. 6 (2022): 2109–2110.

[220] M. Baiersdörfer, G. Boros, H. Muramatsu, et al., “A Facile Method for the Removal of dsRNA Contaminant From in Vitro-Transcribed mRNA,” Mol Ther Nucleic Acids 15 (2019): 26–35.

[221] K. Kariko, M. Buckstein, H. Ni, et al., “Suppression of RNA Recognition by Toll-Like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA,” Immunity 23, no. 2 (2005): 165–175.

[222] K. Karikó, H. Muramatsu, F. A. Welsh, et al., “Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability,” Molecular Therapy 16, no. 11 (2008): 1833–1840.

[223] K. Karikó, H. Muramatsu, J. M. Keller, et al., “Increased Erythropoiesis in Mice Injected With Submicrogram Quantities of Pseudouridine-containing mRNA Encoding Erythropoietin,” Molecular Therapy 20, no. 5 (2012): 948–953.

[224] B. R. Anderson, H. Muramatsu, and S. R. Nallagatla, “Incorporation of Pseudouridine Into mRNA Enhances Translation by Diminishing PKR Activation,” Nucleic Acids Res 38, no. 17 (2010): 5884–5892.

[225] S. Mokuda, H. Watanabe, H. Kohno, et al., “N(1)-methylpseudouridine-incorporated mRNA Enhances Exogenous Protein Expression and Suppresses Immunogenicity in Primary human Fibroblast-Like Synoviocytes,” Cytotechnology 74, no. 4 (2022): 503–514.

[226] A. J. Barbier, A. Y. Jiang, and P. Zhang, “The Clinical Progress of mRNA Vaccines and Immunotherapies,” Nature Biotechnology 40, no. 6 (2022): 840–854.

[227] D. Prokhorova, A. Matveeva, A. Zakabunin, et al., “Influence of N1-Methylpseudouridine in Guide RNAs on CRISPR/Cas9 Activity,” International Journal of Molecular Sciences 24, no. 23 (2023): 17116.

[228] M. Packer, D. Gyawali, R. Yerabolu, et al., “A Novel Mechanism for the Loss of mRNA Activity in Lipid Nanoparticle Delivery Systems,” Nature Communications 12, no. 1 (2021): 6777.

[229] Z. Liu, J. Chen, M. Xu, et al., “Engineered Multi-domain Lipid Nanoparticles for Targeted Delivery,” Chem Soc Rev 54, no. 12 (2025): 5961–5994.

[230] M. van Dülmen, N. Muthmann, and A. Rentmeister, “Chemo-Enzymatic Modification of the 5' Cap Maintains Translation and Increases Immunogenic Properties of mRNA,” Angewandte Chemie (International ed in English) 60, no. 24 (2021): 13280–13286.

[231] S. Sabnis, E. S. Kumarasinghe, T. Salerno, et al., “A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates,” Molecular Therapy 26, no. 6 (2018): 1509–1519.

[232] N. Pardi, A. J. Secreto, X. Shan, et al., “Administration of Nucleoside-modified mRNA Encoding Broadly Neutralizing Antibody Protects Humanized Mice From HIV-1 Challenge,” Nature Communications 8 (2017): 14630.

[233] Y. Xu, S. Ma, H. Cui, et al., “AGILE Platform: A Deep Learning Powered Approach to Accelerate LNP Development for mRNA Delivery,” Nature Communications 15, no. 1 (2024): 6305.

[234] K. Wu, X. Yang, Z. Wang, et al., “Data-balanced Transformer for Accelerated Ionizable Lipid Nanoparticles Screening in mRNA Delivery,” Brief Bioinform 25, no. 3 (2024): bbae186.

[235] H. Tanaka, Y. Sato, T. Nakabayashi, et al., “A Post-Encapsulation Method for the Preparation of mRNA-LNPs via the Nucleic Acid-Bridged Fusion of mRNA-Free LNPs,” Nano Letters 25, no. 16 (2025): 6445–6453.

[236] S. Meulewaeter, G. Nuytten, M. H. Y. Cheng, et al., “Continuous Freeze-drying of Messenger RNA Lipid Nanoparticles Enables Storage at Higher Temperatures,” J Control Release 357 (2023): 149–160.

[237] H. Lv, S. Zhang, B. Wang, et al., “Toxicity of Cationic Lipids and Cationic Polymers in Gene Delivery,” J Control Release 114, no. 1 (2006): 100–10s9.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.